Our data indicated that abnormal expression of XIST was significant correlated with OS (function as oncogene, HR = 0.53, 95% CI: 0.42–0.68, p < 0.00001; function as tumor suppressor, HR = 2.25, 95% CI: 1.15–4.37, p = 0.02), DFS (HR = 0.45; 95% CI: 0.31–0.67, p < 0.0001) tumor types (digestive system carcinoma, HR = 0.50; 95% CI: 0.37–0.69, p < 0.0001; non-digestive system carcinoma, HR = 0.58; 95% CI: 0.39–0.87, p = 0.008), LNM (OR = 0.32, 95% CI: 0.20–0.52, p < 0.00001), DM (OR = 0.36, 95% CI: 0.22–0.60, p < 0.0001) and the tumor stages (OR = 0.43, 95% CI: 0.31–0.60, p < 0.00001). Here, XIST is linked to digestive system carcinoma.